Ibutilide is the only Food and Drug Administration-approved intravenous drug for the rapid termination of atrial fibrillation and flutter. Its mechanism of action is undecided. The drug has been ...

Background: The safety and efficacy of ibutilide in the cardioversion of atrial flutter and atrial fibrillation in children and in patients with congenital heart disease (CHD) is unknown.